Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Earnings Preview: What to Expect From Amgen’s Report

Amgen Inc. (AMGN) is a California-based biopharmaceutical company focused on developing and delivering human therapeutics, especially in oncology, inflammation, bone health, and rare diseases. With a market cap of $159.7 billion, it’s known for blockbuster drugs like Prolia, Enbrel, and Repatha.

The company is expected to release its fiscal Q2 2025 earnings results after the market closes on Tuesday, Aug. 5. Ahead of this event, analysts expect AMGN to report a profit of $5.21 per share, up 4.8% from $4.97 per share in the prior year's quarter. It has consistently surpassed Wall Street's bottom-line estimates in the past four quarters. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.